pcn poster

Posters

Clinical Safety and Efficacy of RL-007 from a Phase2a Study of Cognition in Schizophrenia Patients

Approximately 80% of schizophrenia patients are impacted by significant cognitive impairments. RL-007, an oral pro-cognitive neuromodulator, has been evaluated in pre-clinical and clinica...

Matthew Pando , PhD;

10/26/2023

Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers

The presented study evaluated the CV safety and PK after SDX, a prodrug of d-MPH, relative to Ritalin IR and Ritalin LA. At an SDX dose (200 mg) of 2.5x the molar-equivalent Ritalin doses...

Rene Braeckman , PhD;

10/26/2023

Cardiovascular Burden of Patients Diagnosed With Idiopathic Hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM)

This study compared the odds of cardiovascular (CV) conditions in patients with idiopathic hypersomnia (IH) versus matched non-IH controls using Merative™ MarketScan® administrative claim...

Jed Black , MD;

10/26/2023

Cariprazine as an Adjunctive Treatment for Major Depressive Disorder: Assessment of Benefit and Risk Using Number Needed to Treat and Number Needed to Harm

The benefit-risk profile of cariprazine is favorable for major depressive disorder adjunctive treatment.

Majid Kerolous , PharmD, MPH;

10/26/2023

Categorial Response Rates, Time Course of Response, and Symptom Domains of Response With KarXT (Xanomeline-Trospium) in the Phase 3 EMERGENT-2 Study

KarXT, a combination of xanomeline (dual M1/M4 muscarinic receptor agonist) and trospium (peripherally restricted muscarinic receptor antagonist), showed promising results in the EMERGENT...

Inder Kaul , MD;

10/26/2023

Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study

Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...

Jessica McDonough , MD;

10/26/2023

Changes in Metabolic Parameters Associated With Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis of 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-controlled adjunctive study evalua...

Jazmin Acosta , PhD;

10/26/2023

Characterization of Care Patterns for Patients Newly Diagnosed With Major Depressive Disorder (MDD) in Primary Care Settings: a Retrospective Observational Cohort Study

This retrospective cohort study utilized claims data to examine care patterns of patients newly diagnosed with major depressive disorder (MDD) in outpatient settings. The study provided v...

Laura Lupton , MD;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Bipolar-I Disorder in the US

In this study, a cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hy...

Vakaramoko Diaby ;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Schizophrenia in the US

A cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hypothetical heal...

Vakaramoko Diaby ;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products